Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine to Broaden U.S. Diabetes Treatment Options Oct 16, 2025 06:05AM
Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars Oct 1, 2025 07:30AM
Biocon Biologics Receives U.S. Food and Drug Administration Approval for Bosaya™ and Aukelso™, Denosumab Biosimilars Sep 17, 2025 07:32AM
Biocon Biologics Secures Strong Market Access Coverage for Yesintek™ in the United States Covering 100+ Million Lives May 5, 2025 08:00AM
Biocon Biologics Secures Market Entry Date for Yesafili™, an Interchangeable Biosimilar to Eylea®, in the U.S. Apr 15, 2025 08:01AM


Apr 10, 2025 08:37AM Biocon Biologics Announces U.S. FDA Approval for Jobevne™, Biosimilar Bevacizumab, Expanding Its Oncology Portfolio
Mar 7, 2025 08:01AM Biocon Biologics Announces Positive Results from Phase 3 Study of Yesintek™ Biosimilar to Ustekinumab for Chronic Plaque Psoriasis
Mar 6, 2025 07:00AM Biocon Biologics and Civica, Inc. Collaborate to Expand Insulin Aspart Access in the United States
Feb 24, 2025 07:00AM Biocon Biologics Launches Yesintek™ (ustekinumab-kfce) Biosimilar to Stelara® in the United States
Feb 6, 2025 08:00AM Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis
Jan 9, 2025 07:51AM Biocon Biologics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Sep 25, 2024 01:05AM Biocon Biologics Announces New Dermatology Data to Be Presented at EADV Congress 2024
Aug 29, 2024 01:13AM Biocon Biologics Secures Market Entry for Bmab 1200, a Proposed Biosimilar to Stelara®, in Europe, UK, Canada, and Japan
May 21, 2024 08:00AM Biocon Biologics Obtains U.S. FDA Approval for Biosimilar Aflibercept for Yesafili™. Enters U.S. Ophthalmology Market
Feb 29, 2024 09:56AM Biocon Biologics Secures US Market Entry Date for Bmab 1200, a Proposed Biosimilar to Stelara®
Feb 8, 2024 09:54PM Biocon Biologics Partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab
Nov 30, 2023 05:47AM Biocon Biologics Successfully Completes Integration of Viatris' Biosimilar Business in 31 Countries in Europe
Sep 6, 2023 07:00AM Biocon Biologics Continues to Expand Global Footprint, Completes Integration of Viatris Biosimilars' Business In North America Ahead of Schedule
Jul 24, 2023 06:30AM Biocon Biologics Announces Positive CHMP Opinion for YESAFILI®, Biosimilar Aflibercept
Jul 3, 2023 12:40PM AFTER FIVE YEARS OF SUCCESSFUL EXPERIENCE INTERNATIONALLY, BIOCON BIOLOGICS' HULIO® BIOSIMILAR TO HUMIRA®, NOW AVAILABLE IN THE UNITED STATES
Nov 16, 2021 06:59AM Viatris and Biocon Biologics Announce Launch of Interchangeable SEMGLEE® (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection
Jul 28, 2021 11:29PM Viatris Inc. and Biocon Biologics Receive Historic Approval for First Interchangeable Biosimilar Semglee® (insulin glargine-yfgn injection) for the Treatment of Diabetes
Aug 31, 2020 06:00AM Mylan and Biocon Biologics Announce Launch of Semglee™ (insulin glargine injection) in the U.S. to Expand Access for Patients Living with Diabetes
Jul 21, 2020 02:00AM Biocon Biologics and Voluntis Join Hands for Global Collaboration on Digital Therapeutics for Insulins
Jun 11, 2020 06:35PM Mylan and Biocon Announce U.S. FDA Approval of Semglee™ (insulin glargine injection)
Mar 27, 2020 03:00PM Sun Pharmaceutical Industries, Inc. Donates 2.5 Million Hydroxychloroquine Sulfate Tablets in the U.S. For Potential COVID-19 Treatment
Mar 9, 2020 08:05AM Mylan (MYL) Announces U.S. FDA Accepts BLA Proposed Biosimilar Bevacizumab for Review
Mar 9, 2020 08:00AM U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Bevacizumab for Review
Feb 26, 2020 05:00AM Sun Pharma Launches RIOMET ER Oral Suspension in the U.S.
Dec 2, 2019 07:00AM Mylan and Biocon Launch Trastuzumab Biosimilar, Ogivri™ (trastuzumab-dkst), in the U.S.
May 15, 2019 05:01PM Mylan and Biocon to Present Final Overall Survival Data for Ogivri™ (trastuzumab-dkst), a biosimilar to Herceptin®, at the American Society of Clinical Oncology (ASCO) Annual Meeting
Oct 19, 2018 09:31AM Mylan (MYL), Biocon Announce Positive CHMP Opinion for Ogivri, Biosimilar Trastuzumab
Oct 19, 2018 09:30AM Mylan and Biocon Announce Positive CHMP Opinion for Ogivri®, Biosimilar Trastuzumab
Sep 21, 2018 09:30AM Mylan and Biocon Announce Positive CHMP Opinion for Fulphila®, Biosimilar Pegfilgrastim
Mar 27, 2018 11:00PM Mylan and Biocon Receive Approvals from the European Commission and TGA Australia for Semglee™, Biosimilar Insulin Glargine
Feb 15, 2018 06:55AM CytoSorbents Expands Its Partnership with Biocon to Launch CytoSorb® in Malaysia
Dec 29, 2017 01:30AM Biocon and Mylan's Biosimilar Trastuzumab Receives Approval from ANVISA, Brazil Through their Partner Libbs
Oct 9, 2017 08:00AM Quark Pharmaceuticals, Inc. to Present Preclinical Efficacy Data on Inhaled siRNA Co-Developed with Biocon for Prevention of Primary Graft Dysfunction following Lung Transplantation at the 6th Annual